Project description
Innovative drug discovery platform
Development of new drugs represents very high costs and many drug discovery failures result from off-target toxicology, lack of target efficacy, and poor solubility or bioavailability. The recently developed concept of Leap-to-Lead™ substantially extends synthetic chemical space to include candidate molecules capable to interact with the previously untreatable targets. The concept includes the comprehensive fragment library (CFL) of available fragments with computational connections to a pre-selected set of 850,000 related molecules, and the Syntheverse™ compound database of >500 Billion molecules. The phase 1 project will demonstrate the applicability of photochemical processes for the expansion of the CFL and the commercial feasibility of the platform utilization for collaborative drug discovery.
Objective
Health and wellbeing are among the basic and most important needs of humanity. Medicines have a major impact on the quality of life and are essential for treating various diseases. Despite the numerous achievements of the pharmaceutical industry, there are still diseases without effective treatment. Pharmaceutical industry is continuously searching for new compounds that can become drug candidates against such diseases. Development of one new drug can take about 15 years, cost up to 2-5 billion USD and includes several steps of research and development. The first step of the process is called drug discovery. Our company, BioBlocks is a collaborative medicinal chemistry research organization focused on drug discovery from initial lead discovery to development candidates, serving the needs of our clients: pharmaceutical and biotech companies. Answering to our identified clients’ need, using our experiences, we have developed and patented the Leap-to-Lead™ (L2L) concept, with the aim to expand Drug Discovery beyond its current limits. L2L consists of two major components that work in concert a Comprehensive Fragment Library (CFL), a proprietary collection of available fragments, and Syntheverse™, >500 Billion compound database. The next phase of platform development will expand its scope towards meeting its full potential: making it routine to identify viable new chemical matter for biological pathways that do not have a traditional target. We aim to speed up adding novel physical scaffolds to the CFL, for which we need to improve our internal chemical technology tools, and increase our resources for the project. Thus, we need to get external funding, such as investment and/or grant, e.g. SME Instrument Phase 2. We intend to make a convincing, detailed business plan that will increase our chances for obtaining such subsidy. The objective of this Phase 1 project is to prepare a feasibility study for these activities.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencescomputer and information sciencesdatabases
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health sciencesbasic medicinetoxicology
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
1045 BUDAPEST
Hungary
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.